Bayona J, Chavez-Pachas A M, Palacios E, Llaro K, Sapag R, Becerra M C
Socios En Salud Sucursal Peru/Partners In Health, Lima, Peru.
Int J Tuberc Lung Dis. 2003 Dec;7(12 Suppl 3):S501-9.
Two regions of metropolitan Lima, Peru.
To determine the outcomes of two contact investigation strategies used in therapy enrollment cohorts of patients with multidrug-resistant tuberculosis (MDR-TB).
From 28 August 1996 to 31 December 1999, 91 index patients received individualized MDR-TB therapy (Group A), and from 1 October 1997 to 31 December 1999, another 101 index patients received a standardized MDR-TB regimen (Group B). We conducted a retrospective chart review and home visits to identify secondary cases among close contacts of both of these groups. Group A secondary cases with MDR-TB received therapy based on the drug susceptibility profile of their infecting strain, while Group B secondary cases received standard short-course therapy.
Among 945 close contacts, 72 secondary TB cases (8%) were found. Of 42 who had drug-susceptibility testing, 35 (84%) were MDR-TB, but only seven (17%) had the same drug susceptibility profile as the index case. Cure exceeded 80% in Group A secondary cases, while only half of Group B secondary cases were cured (RR 1.6, 95%CI 1.1-2.2).
Contact investigation protocols coupled with enrollment in MDR-TB therapy are a useful means of detecting and promptly treating persons with infectious MDR-TB. In settings with endemic MDR strains of Mycobacterium tuberculosis, effective therapy of contacts of MDR-TB patients requires knowledge of drug susceptibility for each contact with active disease.
秘鲁利马市的两个地区。
确定在耐多药结核病(MDR-TB)患者治疗登记队列中使用的两种接触者调查策略的结果。
从1996年8月28日至1999年12月31日,91例索引患者接受个体化MDR-TB治疗(A组),从1997年10月1日至1999年12月31日,另外101例索引患者接受标准化MDR-TB治疗方案(B组)。我们进行了回顾性病历审查和家访,以确定这两组密切接触者中的二代病例。A组耐多药结核病二代病例根据其感染菌株的药敏谱接受治疗,而B组二代病例接受标准短程治疗。
在945名密切接触者中,发现了72例二代结核病病例(8%)。在42例进行药敏试验的患者中,35例(84%)为耐多药结核病,但只有7例(17%)的药敏谱与索引病例相同。A组二代病例的治愈率超过80%,而B组二代病例只有一半治愈(RR 1.6,95%CI 1.1-2.2)。
接触者调查方案与耐多药结核病治疗登记相结合是检测和及时治疗传染性耐多药结核病患者的有用手段。在结核分枝杆菌耐多药菌株流行的地区,对耐多药结核病患者的接触者进行有效治疗需要了解每例活动性疾病接触者的药敏情况。